• 1
    Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990; 265: 32736.
  • 2
    Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999; 94: 341320.
  • 3
    Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 735.
  • 4
    Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 13728.
  • 5
    Poulsen LK, Jacobsen N, Sorensen BB, Bergenhem NC, Kelly JD, Foster DC, Thastrup O, Ezban M, Petersen LC. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998; 273: 622832.DOI: 10.1074/jbc.273.11.6228
  • 6
    Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor VIIa. Blood 2003; 102: 170815.
  • 7
    Cirillo P, Cali G, Golino P, Calabro P, Forte L, De Rosa S, Pacileo M, Ragni M, Scopacasa F, Nitsch L, Chiariello M. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 2004; 109: 29116.
  • 8
    Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV. Tissue factor–factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103: 302937.
  • 9
    Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res 2002; 107: 2716.DOI: 10.1016/S0049-3848(02)00345-6
  • 10
    Herbert JM, De Prost D, Ollivier V, Melis E, Carmeliet P. Tissue factor is not involved in the mitogenic activity of factor VIIa. Biochem Biophys Res Commun 2001; 281: 10747.DOI: 10.1006/bbrc.2001.4443
  • 11
    Sorensen BB, Freskgard PO, Nielsen LS, Rao LV, Ezban M, Petersen LC. Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem 1999; 274: 2134954.DOI: 10.1074/jbc.274.30.21349
  • 12
    Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 525560.
  • 13
    Ollivier V, Chabbat J, Herbert JM, Hakim J, De Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000; 20: 137481.
  • 14
    Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003; 1: 1495503.DOI: 10.1046/j.1538-7836.2003.00300.x
  • 15
    Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 2003; 10: 21125.
  • 16
    Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP. Tissue factor—a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86: 33445.
  • 17
    Petersen LC, Thastrup O, Hagel G, Sorensen BB, Freskgard PO, Rao LV, Ezban M. Exclusion of known protease-activated receptors in factor VIIa-induced signal transduction. Thromb Haemost 2000; 83: 5716.
  • 18
    Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 24582.
  • 19
    Smith R, Jenkins A, Lourbakos A, Thompson P, Ramakrishnan V, Tomlinson J, Deshpande U, Johnson DA, Jones R, Mackie EJ, Pike RN. Evidence for the activation of PAR-2 by the sperm protease, acrosin: expression of the receptor on oocytes. FEBS Lett 2000; 484: 28590.DOI: 10.1016/S0014-5793(00)02146-3
  • 20
    Hollenberg MD, Saifeddine M, Zwiers H. Proteinase-activated receptors (PARs): activation of PAR1 and PAR2 by a proteolytic fragment of the neuronal growth associated protein B-50/GAP-43. Can J Physiol Pharmacol 2000; 78: 815.DOI: 10.1139/cjpp-78-1-81
  • 21
    Sawada K, Nishibori M, Nakaya N, Wang Z, Saeki K. Purification and characterization of a trypsin-like serine proteinase from rat brain slices that degrades laminin and type IV collagen and stimulates protease-activated receptor-2. J Neurochem 2000; 74: 17318.DOI: 10.1046/j.1471-4159.2000.0741731.x
  • 22
    Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 2633342.DOI: 10.1074/jbc.M002941200
  • 23
    Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, Yamada N, Nishihara T, Ohira M, Hirakawa K. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 2004; 24: 14016.
  • 24
    Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 2004; 279: 2092734.DOI: 10.1074/jbc.M401430200
  • 25
    Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M, Geppetti P, Emanueli C. Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res 2002; 91: 34652.DOI: 10.1161/01.RES.0000031958.92781.9E
  • 26
    Jin E, Fujiwara M, Pan X, Ghazizadeh M, Arai S, Ohaki Y, Kajiwara K, Takemura T, Kawanami O. Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer 2003; 97: 70313.
  • 27
    Copeland WC, Wang TS. Enzymatic characterization of the individual mammalian primase subunits reveals a biphasic mechanism for initiation of DNA replication. J Biol Chem 1993; 268: 2617989.
  • 28
    Miyazawa H, Izumi M, Tada S, Takada R, Masutani M, Ui M, Hanaoka F. Molecular cloning of the cDNAs for the four subunits of mouse DNA polymerase alpha-primase complex and their gene expression during cell proliferation and the cell cycle. J Biol Chem 1993; 268: 811122.
  • 29
    Moore AL, Wang TS. Down-regulation of genes encoding DNA replication proteins during cell cycle exit. Cell Growth Differ 1994; 5: 48594.
  • 30
    Cloutier S, Hamel H, Champagne M, Yotov WV. Mapping of the human DNA primase 1 (PRIM1) to chromosome 12q13. Genomics 1997; 43: 398401.
  • 31
    Yotov WV, Hamel H, Rivard GE, Champagne MA, Russo PA, Leclerc JM, Bernstein ML, Levy E. Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Genes Chromosomes Cancer 1999; 26: 629.DOI: 10.1002/(SICI)1098-2264(199909)26:1<62::AID-GCC9>3.0.CO;2-F
  • 32
    Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, a Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
  • 33
    Dery O, Thoma MS, Wong H, Grady EF, Bunnett NW. Trafficking of proteinase-activated receptor-2 and beta-arrestin-1 tagged with green fluorescent protein. beta-Arrestin-dependent endocytosis of a proteinase receptor. J Biol Chem 1999; 274: 1852435.DOI: 10.1074/jbc.274.26.18524
  • 34
    Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 82059.
  • 35
    Schlingensiepen R, Brysch W, Schlingensiepen KH. Antisense—From Technology to Therapy, Laboratory Manual and Textbook. Berlin-Vienna: Blackwell Science, 1997.
  • 36
    Momparler RL, Vesely J, Momparler LF, Rivard GE. Synergistic action of 5-aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. Cancer Res 1979; 39: 38227.
  • 37
    Lahaie I, Hardy P, Hou X, Hassessian H, Asselin P, Lachapelle P, Almazan G, Varma DR, Morrow JD, Roberts LJ 2nd, Chemtob S. A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2 alpha on retinal vessels. Am J Physiol 1998; 274: R140616.
  • 38
    Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 344050.
  • 39
    Gobeil F Jr, Bernier SG, Vazquez-Tello A, Brault S, Beauchamp MH, Quiniou C, Marrache AM, Checchin D, Sennlaub F, Hou X, Nader M, Bkaily G, Ribeiro-da-Silva A, Goetzl EJ, Chemtob S. Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J Biol Chem 2003; 278: 3887583.
  • 40
    Han H, Rifkind JM, Mildvan AS. Role of divalent cations in the 3′,5′-exonuclease reaction of DNA polymerase I. Biochemistry 1991; 30: 111048.
  • 41
    Inui T, Shinomiya N, Fukasawa M, Kuranaga N, Ohkura S, Seki S. Telomerase activation and MAPK pathways in regenerating hepatocytes. Hum Cell 2001; 14: 27582.
  • 42
    Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10: 5029.
  • 43
    Luther T, Mackman N. Tissue factor in the heart. Multiple roles in hemostasis, thrombosis, and inflammation. Trends Cardiovasc Med 2001; 11: 30712.
  • 44
    Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 2000; 95: 31338.
  • 45
    Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 77427.
  • 46
    Vouret-Craviari V, Grall D, Van Obberghen-Schilling E. Modulation of Rho GTPase activity in endothelial cells by selective proteinase-activated receptor (PAR) agonists. J Thromb Haemost 2003; 1: 110311.